这不仅是手术机器人企业的舞台，更是技术路线、供应链变革、医院系统升级、国际趋势对话的交汇点。在这 里，不只讨论"哪款设备领先"，更定义 未来的医院如何因机器人重构 。 欢迎厂商赞助大会 ，请联系微信号suribot21，或手机号13552754250 普通观众报名，请等待通知 第三届全球手术机器人大会 Global Medical Robotics Conference 2025 暨MedRobot行业颁奖典礼 一、活动日期 2025年9月4日-6日（星期四、五、六） 2025年，医疗机器人产业已进入深水区。产品形态不断演进，临床路径逐步清晰，资本趋于冷静，产业生态日 趋复杂。 第三届全球手术机器人大会，以 " MedRobot Next｜下一站技术未来 " 为主题，聚焦智能手术系统的系统化升 级、全链条生态构建与全球化路径。 【研发者专场｜医工融合与技术转化】 二、活动地点 北京市 中关村自主创新示范区展示中心 三、 MedRobot Next｜下一站技术未来 【开幕式】 【参观机器人租赁医院落地场景】 （仅限受邀） 【手术机器人高管晚宴 】 （仅限受邀） 多位政府与产业机构领导致辞 《全球手术机器人行业报 ...

思宇往期活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 由思宇MedTech主办的 第二届全球医疗科技大会 ， 将于2025年7月17日在北京中关村展示中心举行。作 为专注于医疗器械的高规格行业大会，企业参展不仅是一次线下交流，更是一次精准的品牌曝光机会。 大会 聚焦"前沿技术 · 从研发走向临床应用" 。目前， 招商已经开始， 展位有限，欢迎有意企业抓紧对接。 权益包括但不限于： 商务合作，联系方式如下。 # 大会概况 一、会议地点 ： 中关村展示中心会议中心（北京市海淀区新建宫门路2号） 六、大会议程（拟） 工作微信号： suribot22 手机号： 13552754250 也可以直接联系主编赵清、Alice、Jacky、Ziana 等任何思宇团队的工作人员。 以下为思宇此前举办的大会展位示意图，供参考： 主题演讲 大会现场品牌展位 企业宣传资料发放 活动现场环节嵌入品牌标识 本次大会将邀请来自影像设备、AI平台、高值耗材、能量系统、材料技术等方向的上市公司、创业企业等，分 享 产品创新、技术落地、医工协同等方面的实践经验。 本届大会将重点探讨以下话题 ...

Core Viewpoint - The launch of the "Weizhi Code, Smart Healthcare. Coding the Future" AI medical coding cloud platform in Weifang marks a significant step in the digital transformation of healthcare in the region, integrating advanced technologies to enhance medical coding accuracy and efficiency [1][3]. Group 1: Event Overview - The AI medical coding cloud platform was introduced at a conference organized by the Weifang Health Commission and Weifang People's Hospital, attended by key figures in the healthcare sector [1]. - The event included a systematic introduction to the "Weizhi Code - AI Coding Cloud Platform," showcasing its development background, achievements, and future plans, along with a demonstration of its functionalities [3]. Group 2: Platform Features and Benefits - The platform utilizes large language model technology for intelligent semantic recognition and medical terminology parsing, enabling automatic extraction of key information from medical records and matching standard codes, thereby improving coding accuracy and efficiency [5]. - It aims to unify coding standards across medical institutions, facilitating real-time data sharing and intelligent verification of coding data, which supports medical quality monitoring and cost control [5]. - The successful establishment of the platform signifies a solid advancement in smart healthcare construction in Weifang, with plans to integrate Western medical coding with traditional Chinese medicine practices [5]. Group 3: Future Plans and Collaboration - The "Weizhi Code" will develop a comprehensive output model consisting of one technical platform, three supporting services, and multiple scenario-based modules, promoting collaboration among government, medical institutions, and enterprises [5]. - The initiative aims to create a growth system characterized by "three-level empowerment, two-level undertaking, and grassroots adaptation," ensuring that smart healthcare benefits a broader population and providing a model for digital transformation in healthcare [5].

Core Viewpoint - The recent announcement of measures to support the high-quality development of innovative drugs has also positively impacted the high-end medical device sector, with the National Medical Products Administration (NMPA) introducing specific policies to enhance innovation in this field [1][3]. Group 1: Policy Measures - The NMPA's announcement includes ten specific measures aimed at optimizing special approval processes and improving classification and naming principles for high-end medical devices [1]. - The measures emphasize a full lifecycle regulatory approach to support significant innovations in high-end medical devices, facilitating the transformation of new technologies, materials, and methods into marketable products [1][3]. - The measures are expected to enhance the efficiency of material submissions, approvals, and research and development for companies in the medical device industry [1][4]. Group 2: Market Impact - Following the announcement, several medical device companies saw significant stock price increases, with companies like Hotgen Biotech rising by 20% and others like Zhongyuan Union and Jianfan Bio increasing by nearly 10% [2]. - The measures are anticipated to accelerate the market entry of high-end medical devices, particularly those related to artificial intelligence and new biological materials [3]. Group 3: Regulatory Improvements - The measures propose to streamline the approval process for high-end medical devices, reducing the average approval cycle from 12 months to potentially 9 or 10 months [3][4]. - The NMPA aims to enhance the standardization of medical devices, including the development of standards for medical robots and artificial intelligence devices [4][6]. - The focus will also be on improving post-market surveillance and quality safety monitoring for innovative products [6]. Group 4: Internationalization and Challenges - The measures support high-end medical device companies in participating in international standard-setting and expanding their global market presence [7]. - Despite advancements, challenges remain for Chinese companies in terms of technology implementation and market competition with established Western firms, which may require significant time and investment [8].

Group 1 - The Chinese government has introduced 24 measures to comprehensively promote the protection and management of rivers and lakes [3] - The Ministry of Industry and Information Technology has deployed a pilot program for number protection services [11] - The National Medical Products Administration has released ten measures to support the innovation and development of high-end medical devices [12] Group 2 - Fixed asset investment in rural roads exceeded 130 billion yuan in the first five months of this year [6] - The Shanghai Free Trade Zone will replicate and promote 77 pilot measures [7] - The number of international shipping vessels entering and leaving Shanghai Port has reached a historical high for the same period [14]

Group 1: Impact on Healthcare Sector - The "Big and Beautiful" bill is expected to cut approximately $900 billion in Medicaid spending over the coming years, reversing many advancements made during the Biden and Obama administrations in healthcare [4] - The bill introduces stricter requirements for Medicaid beneficiaries, potentially leading to millions losing their healthcare coverage [5] - Companies heavily exposed to Medicaid, such as Elevance Health, Centene, and Molina Healthcare, are likely to see a direct impact on their revenues due to a decrease in Medicaid enrollment [5][6] Group 2: Effects on Renewable Energy Industry - The bill cancels several clean energy incentives from the Biden administration, imposing restrictions on solar and wind energy while encouraging fossil fuel production [7] - Changes in tax measures are expected to increase the burden on the renewable energy sector by approximately $4 billion to $7 billion [8] - The bill threatens around $450 billion in infrastructure investments in the renewable sector, potentially leading to the loss of about 300 gigawatts of solar and wind projects over the next decade [8] Group 3: Benefits to Corporations and High-Income Individuals - The bill reinstates tax policies that allow businesses to fully deduct equipment costs in the year of purchase, benefiting organizations like the U.S. Chamber of Commerce [11] - High-income households are projected to see a net income increase of nearly $13,000 after taxes and transfers, while middle-income families will see a smaller increase of $1,430 [12] - The bill provides additional tax incentives for semiconductor manufacturers building facilities in the U.S., aiming to stimulate investment in the manufacturing sector [11]

Group 1 - The core viewpoint of the article highlights the significance of technological innovation as a driving force for high-quality development in the healthcare industry, with a focus on the achievements of YOUMAGIC Shuliti R&D Company and its subsidiary Weimai Medical [3][5] - YOUMAGIC Shuliti R&D Company has established a strong foundation in scientific research, leveraging over 30 years of RF technology experience from Tsinghua University's Engineering Physics Department and nearly 70 years of high-energy physics research to enhance its technological innovation capabilities [3][5] - The company has developed a comprehensive product line in both serious medical and consumer healthcare sectors, with multiple products receiving NMPA Class III certification, indicating its potential for high-energy development [3][5] Group 2 - YOUMAGIC Shuliti R&D Company has demonstrated a keen market insight, adapting to the trends of "precision medicine" and the widespread application of AI technology in the healthcare sector, which is reshaping the industry landscape [5][7] - The company's flagship product, the YOUMAGIC Shuliti next-generation high-energy monopolar RF device, is the first in China to receive both NMPA and FDA dual certification, catering to diverse consumer treatment needs with customizable treatment plans [5][7] - Future plans for YOUMAGIC Shuliti include deepening its focus on precision medicine, accelerating the development of a multi-head product matrix, and enhancing the application of AI technologies in healthcare to provide better, more precise, and comfortable medical solutions globally [7]

7月4日，迪瑞医疗今日收盘14.03元，下跌1.06%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到106.87倍，总市值38.26亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迪瑞医疗106.8726.961.8538.26亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科医疗 10.4711.290.93165.45亿3新华医疗14.4313.381.1892.52亿4奥美医疗15.3215.011.5755.35亿5山东药玻 15.3915.431.77145.53亿6振德医疗15.4714.580.9856.17亿7康德莱15.7315.741.3033.89亿8维力医疗 16.4917.141.9337.60亿9九强生物16.4915.332.0281.66亿10奥泰生物16.6117.511.3452.96亿11安杰思 17.6117.812.1352.26亿12安图生物18.8317.982.42214.74亿 来源：金融界 迪瑞医疗科技股份有限公司的 ...

Core Viewpoint - The National Health Commission emphasizes the importance of distinguishing between medical and non-medical beauty services, highlighting the risks associated with non-professional practices in medical aesthetics [1][2][3] Group 1: Medical vs. Non-Medical Aesthetics - Medical aesthetics involves invasive techniques such as surgeries and injections aimed at repairing or reshaping appearance, while non-medical beauty services are non-invasive, like applying face masks [1] - Medical institutions must meet strict regulatory requirements to ensure safety and quality in medical aesthetic services, which can be verified through the National Health Commission's official website [1] Group 2: Risks of Non-Medical Aesthetic Practices - Increased risk of infection due to non-sterile environments and improper handling in non-medical settings, potentially leading to severe complications like sepsis [2] - Higher likelihood of adverse reactions from unregulated injection materials, which may cause serious allergic reactions or other health issues [2] - Greater risk of embolism from injections performed by non-professionals, which can result in severe consequences such as skin necrosis, blindness, or stroke [2][3] - Non-medical institutions lack effective emergency response measures, making it difficult to address complications like allergies or embolisms promptly [3]

Core Viewpoint - Alibaba plans to issue HKD 12 billion zero-interest exchangeable bonds, which may be interpreted as a disguised reduction of its stake in Alibaba Health, leading to a significant drop in Alibaba Health's stock price [1][4]. Summary by Sections Bond Issuance Details - The bonds will have a principal amount of approximately HKD 12 billion and are set to mature in 2032, with an initial exchange price of HKD 6.23 per share of Alibaba Health, which is about 50% higher than its current trading price [2][3]. Purpose of Fundraising - The net proceeds from the bond issuance are intended for general corporate purposes, including investments to support the development of Alibaba's cloud infrastructure and international business [4]. Impact on Alibaba Health - Alibaba holds approximately 64% of Alibaba Health, which has a market value of HKD 682 billion as of July 4, 2023. The issuance of these bonds is not expected to dilute shareholder equity in Alibaba Health [4][8]. Market Reactions and Investor Sentiment - Following the announcement, Alibaba Health's stock fell by 6.42%, while Alibaba's stock experienced a slight decline before recovering. Analysts suggest that the bond issuance is a flexible capital management strategy rather than an immediate asset sale [1][7][9]. Financial Performance - For the fiscal year 2025, Alibaba Health reported total revenue of HKD 30.6 billion, a year-on-year increase of 13.2%, and adjusted net profit of HKD 1.95 billion, up 35.6%. Alibaba's revenue for the same period was HKD 996.35 billion, reflecting a 6% year-on-year growth [5][10]. Strategic Considerations - Analysts emphasize that the bond issuance should be viewed from a strategic and value investment perspective, as it does not indicate a negative outlook on Alibaba Health's business model. The focus should remain on the long-term growth potential of the digital healthcare sector [10].